Planned intervention: On Wednesday June 26th 05:30 UTC Zenodo will be unavailable for 10-20 minutes to perform a storage cluster upgrade.
Published March 31, 2020 | Version v1
Dataset Open

Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches


Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, there is a single drug approved as first-line systemic therapy in advanced unresectable HCC, providing a very limited survival benefit. In earlier stages, 5-year survival rates after surgical and loco-regional therapies are extremely variable depending on the stage of disease.

Nevertheless, HCC is considered an immunogenic tumor arising in chronically inflamed livers.  

In such a scenario, immunotherapy strategies for HCC, in particular combinations including cancer vaccines, may represent a key therapeutic tool to improve clinical outcome in HCC patients.  However, a lot of improvement is needed given the disappointing results obtained so far.


Files (94.5 kB)

Name Size Download all
94.5 kB Download

Additional details

Related works

Is cited by
Journal article: 10.1016/j.canlet.2019.12.029 (DOI)


HEPAVAC – Cancer Vaccine development for Hepatocellular Carcinoma 602893
European Commission